Last reviewed · How we verify

NCT04742257: RECOVER

Study Evaluating MyoRegulator® Treatment in Post-Stroke Upper Limb Spasticity

Terminated NA Last updated 15 August 2024
What this trial tests

NA trial testing MyoRegulator® device in Muscle Spasticity in 28 participants. Terminated before completion.

Timeline
4 March 2022
Primary endpoint
30 June 2024
30 June 2024

Quick facts

Lead sponsorPathMaker Neurosystems Inc.
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment28
Start date4 March 2022
Primary completion30 June 2024
Estimated completion30 June 2024
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

PathMaker Neurosystems Inc. — full company profile →

Who can join

Adults 18 to 85, any sex, with Muscle Spasticity or Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, randomized, double-blind (patient and evaluator), sham-controlled study to be conducted in stroke patients with upper-extremity spasticity. The main objectives of this study are to evaluate the performance and safety of the MyoRegulator® device in active- versus sham-treated patients after 5 consecutive days of treatment. The MyoRegulator® device is a non-significant risk (NSR) investigational non-invasive neuromodulation device that uses multi-site direct current (multi-site DCS) stimulation for the treatment of muscle spasticity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Muscle Spasticity

Currently open trials in the same condition.

Other PathMaker Neurosystems Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04742257.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing